Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
OPERATING ACTIVITIES
Net income		$ (14.3)	$ 10.3
Adjustments to reconcile net income to net cash provided by operating activities:
Bridge loan facility fees		26.1	0.0
Depreciation and amortization		33.3	20.5
Employee share-based compensation expense		4.0	3.3
Financing costs amortization		2.8	0.7
Unrealized foreign currency transaction gain		1.7	(1.1)
Unrealized loss on investments in equity securities		2.0	2.6
Equity in loss of unconsolidated affiliates		0.5	0.3
Other non-cash operating activities		0.1	2.0
Changes in assets and liabilities, net of acquisitions:
Accounts receivable		(6.6)	(17.2)
Inventories		10.4	(35.0)
Unbilled contract revenues and other assets		174.9	(36.1)
Accounts payable and other liabilities		(273.8)	(3.5)
Customer advances and billings in excess of contract revenue		6.8	31.0
Net Cash Used In Operating Activities		(32.1)	(22.2)
INVESTING ACTIVITIES
Acquisition of businesses, net of cash acquired		(4,339.8)	(0.8)
Investments		(2.1)	(3.9)
Capital expenditures		(31.4)	(12.6)
Proceeds from sale of assets		0.1	0.0
Government grants and other		(0.6)	(0.2)
Net Cash Used In Investing Activities		(4,373.8)	(17.5)
FINANCING ACTIVITIES
Borrowings on revolving credit facility		634.8	254.0
Repayments on revolving credit facility		(45.0)	(235.9)
Borrowings on term loan		1,497.2	0.0
Payments for debt issuance costs		(121.5)	0.0
Proceeds from issuance of common stock, net		11.7	0.0
Proceeds from exercise of stock options		0.1	1.0
Common stock repurchases from share-based compensation plans		(2.6)	(3.2)
Dividends paid on mandatory convertible preferred stock		(6.9)	0.0
Net Cash Provided By Financing Activities		1,967.8	15.9
Effect of exchange rate changes on cash and cash equivalents		2.2	1.3
Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents		(2,435.9)	(22.5)
Cash, cash equivalents, restricted cash, and restricted cash equivalents at beginning of period		2,605.3	122.4
CASH, CASH EQUIVALENTS, RESTRICTED CASH, AND RESTRICTED CASH EQUIVALENTS AT END OF PERIOD	[1],[2]	$ 169.4	$ 99.9

[1] Net cash used in operating activities includes net out-of-pocket payments in connection with settlements related to our divested cryobiological products business. For further information regarding our discontinued operations, refer to Note 2, “Discontinued Operations.”

[2] Includes restricted cash and restricted cash equivalents of $2.5 and $1,941.7 classified within restricted cash as of March 31, 2023 and December 31, 2022, respectively. For further information regarding restricted cash and restricted cash equivalents balances, refer to Note 9, “Debt and Credit Arrangements.”